BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra reports that all operating areas are growing, and the Group’s sales for the fourth quarter surpassed earlier record-breaking levels.

Pierre Fabre Laboratories announced the filing of an investigational new drug application to the U.S. Food and Drug Administration to initiate a first-in-human Phase I/II clinical trial with PFL-002/VERT-002 for solid tumors including non-small cell lung cancer.

Curium, a world leader in nuclear medicine, announced that it has signed a long-term partnership with the Institut Laue-Langevin for irradiation services at their high-flux nuclear reactor in Grenoble, France to produce non-carrier added lutetium-177.

Vir Biotechnology, Inc. announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta.

With new features that make it faster and easier to use, Novoxel Inc. announces the launch of Tixel 2® to the USA.

MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.

PathMaker Neurosystems Inc. announced that it has received a funding award of $2.16 million from the Congressionally Directed Medical Research Program at the United States Department of Defense’s U.S. Army Medical Research and Development Command, as part of its FY23 Amyotrophic Lateral Sclerosis Research Program Pilot Clinical Trial Award.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13th, 2024.

Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.

Mesa Laboratories, Inc., a global leader in the design and manufacture of life science tools and critical quality control solutions, announced results for its fourth fiscal quarter and fiscal year ended March 31, 2024.